About Us
Overview
Our Business
Board of Directors
Executive Leadership Team
Biocon Biologics Malaysia
Scientific Publications
Awards & Recognition
Our Legacy
Products
Overview
Product Locator
Business
Overview
Global Biosimilars Portfolio
Oncology
Immunology
Diabetology
Ophthalmology
Bone Health & Others
Global Footprint
Partners
Branded Formulations India
Metabolics
Oncology
Immunotherapy
Nephrology
CCD
COVID-19 Care Portfolio
Capabilities
Research & Development
Quality & Compliance
Global Scale Manufacturing
Biocon Biologics Malaysia
Commitment
Overview
Investors
Overview
Governance & Policies
News
Overview
Press Releases
Company Statements
Stories
Media Contacts
Careers
Working With Us
Now Hiring
Stories
Contact Us
Brand Stories
Employee Stories
Patient Stories
Company Statements 2017
Biocon Biologics
/
News – Posts
/
Company Statements
/
Company Statements 2017
Resubmission of Biosimilar Trastuzumab and Pegfilgrastim Dossiers with EMA
Tue, 07-Nov-2017
Posted by: Biocon Biologics
No Comments
US FDA Issues Complete Response Letter for Proposed Biosimilar Pegfilgrastim
Tue, 10-Oct-2017
Posted by: Biocon Biologics
No Comments
Biocon’s Insulins facility in Malaysia Receives EU GMP Compliance Certificate
Thu, 07-Sep-2017
Posted by: Biocon Biologics
No Comments
USFDA Target Action Date for Trastuzumab reset to December 3, 2017
Wed, 30-Aug-2017
Posted by: Biocon Biologics
No Comments
Status of EMA Dossiers
Wed, 16-Aug-2017
Posted by: Biocon Biologics
No Comments
USFDA visit in May/June 2017
Thu, 03-Aug-2017
Posted by: Biocon Biologics
No Comments
Biocon Receives GMP approval for Biologics Drug Substance facilities from French Regulator; Drug Product facility to be re-inspected
Sun, 09-Jul-2017
Posted by: Biocon Biologics
No Comments
Media Reports on USFDA 483s
Fri, 05-May-2017
Posted by: Biocon Biologics
No Comments
